Summary
Global Markets Direct’s, ‘Respiratory Syncytial Virus Fusion Protein (RSV F Protein) - Pipeline Review, H2 2016’, provides in depth analysis on Respiratory Syncytial Virus Fusion Protein (RSV F Protein) targeted pipeline therapeutics.
The report provides comprehensive information on the Respiratory Syncytial Virus Fusion Protein (RSV F Protein), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Respiratory Syncytial Virus Fusion Protein (RSV F Protein) targeted therapeutics development and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.
Scope
- The report provides a snapshot of the global therapeutic landscape for Respiratory Syncytial Virus Fusion Protein (RSV F Protein)
- The report reviews Respiratory Syncytial Virus Fusion Protein (RSV F Protein) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Respiratory Syncytial Virus Fusion Protein (RSV F Protein) targeted therapeutics and enlists all their major and minor projects
- The report assesses Respiratory Syncytial Virus Fusion Protein (RSV F Protein) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Respiratory Syncytial Virus Fusion Protein (RSV F Protein) targeted therapeutics
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Respiratory Syncytial Virus Fusion Protein (RSV F Protein)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Respiratory Syncytial Virus Fusion Protein (RSV F Protein) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Companies Mentioned
Ablynx NV
Agilvax Inc
Aridis Pharmaceuticals LLC
Aviragen Therapeutics Inc
Bavarian Nordic A/S
Celltrion, Inc.
Emergent BioSolutions Inc.
F. Hoffmann-La Roche Ltd.
Gene Techno Science Co., Ltd.
GenVec, Inc.
Gilead Sciences, Inc.
GlaxoSmithKline Plc
iBio, Inc.
Johnson & Johnson
mAbxience S.A.
MedImmune LLC
Medivir AB
Mucosis B.V.
Navigen Pharmaceuticals, Inc.
NeuClone Pty Ltd
Novavax, Inc.
Regeneron Pharmaceuticals Inc
Takeda Pharmaceutical Company Limited
TechnoVax, Inc.
The International Biotechnology Center (IBC) Generium
Vaxart Inc
VBI Vaccines Inc
VLP Biotech, Inc.
'
Table of Contents
Table of Contents 2
List of Tables 8
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Respiratory Syncytial Virus Fusion Protein (RSV F Protein) Overview 11
Therapeutics Development 12
Respiratory Syncytial Virus Fusion Protein (RSV F Protein) - Products under Development by Stage of Development 12
Respiratory Syncytial Virus Fusion Protein (RSV F Protein) - Products under Development by Therapy Area 13
Respiratory Syncytial Virus Fusion Protein (RSV F Protein) - Products under Development by Indication 14
Respiratory Syncytial Virus Fusion Protein (RSV F Protein) - Pipeline Products Glance 15
Late Stage Products 15
Early Stage Products 16
Respiratory Syncytial Virus Fusion Protein (RSV F Protein) - Products under Development by Companies 17
Respiratory Syncytial Virus Fusion Protein (RSV F Protein) - Products under Development by Universities/Institutes 21
Respiratory Syncytial Virus Fusion Protein (RSV F Protein) - Therapeutics Assessment 23
Assessment by Monotherapy/Combination Products 23
Assessment by Mechanism of Action 24
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Respiratory Syncytial Virus Fusion Protein (RSV F Protein) - Companies Involved in Therapeutics Development 29
Ablynx NV 29
Agilvax Inc 30
Aridis Pharmaceuticals LLC 31
Aviragen Therapeutics Inc 32
Bavarian Nordic A/S 33
Celltrion, Inc. 34
Emergent BioSolutions Inc. 35
F. Hoffmann-La Roche Ltd. 36
Gene Techno Science Co., Ltd. 37
GenVec, Inc. 38
Gilead Sciences, Inc. 39
GlaxoSmithKline Plc 40
iBio, Inc. 41
Johnson & Johnson 42
mAbxience S.A. 43
MedImmune LLC 44
Medivir AB 45
Mucosis B.V. 46
Navigen Pharmaceuticals, Inc. 47
NeuClone Pty Ltd 48
Novavax, Inc. 49
Regeneron Pharmaceuticals Inc 50
Takeda Pharmaceutical Company Limited 51
TechnoVax, Inc. 52
The International Biotechnology Center (IBC) Generium 53
Vaxart Inc 54
VBI Vaccines Inc 55
VLP Biotech, Inc. 56
Respiratory Syncytial Virus Fusion Protein (RSV F Protein) - Drug Profiles 57
(human parainfluenza virus [serotype 1] + respiratory syncytial virus) vaccine - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
(influenza (virus like particle) + respiratory syncytial virus) vaccine - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
AK-0529 - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
ALX-0171 - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
AR-201 - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
AX-14 - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
BTA-585 - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
CR-32T - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
DT-preF - Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
GNR-007 - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
GV-2311 - Drug Profile 72
Product Description 72
Mechanism Of Action 72
R&D Progress 72
JNJ-61187165AAA - Drug Profile 74
Product Description 74
Mechanism Of Action 74
R&D Progress 74
JNJ-61187191AAA - Drug Profile 75
Product Description 75
Mechanism Of Action 75
R&D Progress 75
JNJ-64400141 - Drug Profile 76
Product Description 76
Mechanism Of Action 76
R&D Progress 76
MEDI-7510 - Drug Profile 77
Product Description 77
Mechanism Of Action 77
R&D Progress 77
MEDI-8897 - Drug Profile 79
Product Description 79
Mechanism Of Action 79
R&D Progress 79
Monoclonal Antibodies to Inhibit RSV-G and F Proteins for RSV Infections - Drug Profile 81
Product Description 81
Mechanism Of Action 81
R&D Progress 81
Monoclonal Antibody to Inhibit RSV-G and RSV-F for RSV Infections - Drug Profile 82
Product Description 82
Mechanism Of Action 82
R&D Progress 82
MVA-RSV - Drug Profile 83
Product Description 83
Mechanism Of Action 83
R&D Progress 83
palivizumab biosimilar - Drug Profile 84
Product Description 84
Mechanism Of Action 84
R&D Progress 84
palivizumab biosimilar - Drug Profile 85
Product Description 85
Mechanism Of Action 85
R&D Progress 85
palivizumab biosimilar - Drug Profile 86
Product Description 86
Mechanism Of Action 86
R&D Progress 86
palivizumab biosimilar - Drug Profile 87
Product Description 87
Mechanism Of Action 87
R&D Progress 87
palivizumab biosimilar - Drug Profile 88
Product Description 88
Mechanism Of Action 88
R&D Progress 88
palivizumab biosimilar - Drug Profile 89
Product Description 89
Mechanism Of Action 89
R&D Progress 89
presatovir - Drug Profile 90
Product Description 90
Mechanism Of Action 90
R&D Progress 90
respiratory syncytial virus (virus like particle) vaccine - Drug Profile 92
Product Description 92
Mechanism Of Action 92
R&D Progress 92
respiratory syncytial virus (virus like particle) vaccine - Drug Profile 93
Product Description 93
Mechanism Of Action 93
R&D Progress 93
respiratory syncytial virus (virus like particle) vaccine - Drug Profile 94
Product Description 94
Mechanism Of Action 94
R&D Progress 94
respiratory syncytial virus (virus like particle) vaccines - Drug Profile 95
Product Description 95
Mechanism Of Action 95
R&D Progress 95
respiratory syncytial virus immune globulin (human) - Drug Profile 96
Product Description 96
Mechanism Of Action 96
R&D Progress 96
respiratory syncytial virus vaccine - Drug Profile 97
Product Description 97
Mechanism Of Action 97
R&D Progress 97
respiratory syncytial virus vaccine - Drug Profile 99
Product Description 99
Mechanism Of Action 99
R&D Progress 99
respiratory syncytial virus vaccine - Drug Profile 109
Product Description 109
Mechanism Of Action 109
R&D Progress 109
respiratory syncytial virus vaccine - Drug Profile 110
Product Description 110
Mechanism Of Action 110
R&D Progress 110
respiratory syncytial virus vaccine - Drug Profile 111
Product Description 111
Mechanism Of Action 111
R&D Progress 111
respiratory syncytial virus vaccine - Drug Profile 112
Product Description 112
Mechanism Of Action 112
R&D Progress 112
respiratory syncytial virus vaccine - Drug Profile 113
Product Description 113
Mechanism Of Action 113
R&D Progress 113
respiratory syncytial virus vaccine - Drug Profile 114
Product Description 114
Mechanism Of Action 114
R&D Progress 114
RSV-001 - Drug Profile 115
Product Description 115
Mechanism Of Action 115
R&D Progress 115
RV-521 - Drug Profile 116
Product Description 116
Mechanism Of Action 116
R&D Progress 116
Small Molecules to Inhibit Respiratory Syncytial Virus Fusion Protein for RSV Infections - Drug Profile 117
Product Description 117
Mechanism Of Action 117
R&D Progress 117
suptavumab - Drug Profile 118
Product Description 118
Mechanism Of Action 118
R&D Progress 118
SynGEM - Drug Profile 119
Product Description 119
Mechanism Of Action 119
R&D Progress 119
Respiratory Syncytial Virus Fusion Protein (RSV F Protein) - Dormant Projects 121
Respiratory Syncytial Virus Fusion Protein (RSV F Protein) - Discontinued Products 122
Respiratory Syncytial Virus Fusion Protein (RSV F Protein) - Featured News & Press Releases 123
Oct 31, 2016: ReViral Initiates Phase 1 Clinical Trial of Potent Oral Inhibitor Against Respiratory Syncytial Virus 123
Oct 18, 2016: Bavarian Nordic Announces Initiation of Phase 2 Clinical Trial of RSV Vaccine 123
Sep 29, 2016: Bavarian Nordic Announces Presentation Of Phase 1 Data For Its RSV Vaccine At International RSV Symposium 124
Sep 15, 2016: Novavax Announces Topline RSV F Vaccine Data from Two Clinical Trials in Older Adults 124
Aug 11, 2016: Navigen Announces $3MM Phase II NIH SBIR Award to Support the Development of its Anti-RSV Compound to Prevent and Treat RSV Infections in Children and Adults 125
Jul 12, 2016: Aviragen Therapeutics Resumes Enrollment in Phase 2a RSV Challenge Trial 126
Jul 12, 2016: Aviragen Therapeutics Resumes Enrollment in Phase 2a RSV Challenge Trial 126
Jul 06, 2016: Agilvax Receives SBIR Grant To Advance Development Of A VLP Based RSV Vaccine 127
Jun 28, 2016: Vaxart Initiates Clinical Development of First Oral RSV Vaccine 127
Jun 02, 2016: Novavax Announces New Seasonal Combination Respiratory Vaccine Program 128
May 26, 2016: Aviragen Therapeutics Provides Update on Phase 2a Trial of BTA585 for the Treatment of RSV Infections 129
May 25, 2016: U.S. FDA Grants Fast Track Designation to Novavax RSV F Vaccine for Older Adults 129
May 23, 2016: Bavarian Nordic Announces Positive Top Line Results from a Phase 1 Trial of a Novel, Broad Spectrum RSV Vaccine in Healthy Adult and Elderly Populations 130
May 03, 2016: Ablynx reports positive top line results for its inhaled Anti-RSV Nanobody (ALX-0171) in a phase I/IIa Study in infants hospitalized with a RSV infection 131
Apr 11, 2016: Biota Initiates Phase 2a Efficacy Study of BTA585 for the Treatment of RSV Infections 132
Appendix 133
Methodology 133
Coverage 133
Secondary Research 133
Primary Research 133
Expert Panel Validation 133
Contact Us 133
Disclaimer 134
List of Tables
Number of Products under Development for, H2 2016 12
Number of Products under Development by Therapy Area, H2 2016 13
Number of Products under Development by Indication, H2 2016 14
Comparative Analysis by Late Stage Development, H2 2016 15
Comparative Analysis by Early Stage Products, H2 2016 16
Number of Products under Development by Companies, H2 2016 17
Products under Development by Companies, H2 2016 18
Products under Development by Companies, H2 2016 (Contd..1) 19
Products under Development by Companies, H2 2016 (Contd..2) 20
Number of Products under Investigation by Universities/Institutes, H2 2016 21
Products under Investigation by Universities/Institutes, H2 2016 22
Assessment by Monotherapy/Combination Products, H2 2016 23
Number of Products by Stage and Mechanism of Action, H2 2016 24
Number of Products by Stage and Route of Administration, H2 2016 26
Number of Products by Stage and Molecule Type, H2 2016 28
Pipeline by Ablynx NV, H2 2016 29
Pipeline by Agilvax Inc, H2 2016 30
Pipeline by Aridis Pharmaceuticals LLC, H2 2016 31
Pipeline by Aviragen Therapeutics Inc, H2 2016 32
Pipeline by Bavarian Nordic A/S, H2 2016 33
Pipeline by Celltrion, Inc., H2 2016 34
Pipeline by Emergent BioSolutions Inc., H2 2016 35
Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 36
Pipeline by Gene Techno Science Co., Ltd., H2 2016 37
Pipeline by GenVec, Inc., H2 2016 38
Pipeline by Gilead Sciences, Inc., H2 2016 39
Pipeline by GlaxoSmithKline Plc, H2 2016 40
Pipeline by iBio, Inc., H2 2016 41
Pipeline by Johnson & Johnson, H2 2016 42
Pipeline by mAbxience S.A., H2 2016 43
Pipeline by MedImmune LLC, H2 2016 44
Pipeline by Medivir AB, H2 2016 45
Pipeline by Mucosis B.V., H2 2016 46
Pipeline by Navigen Pharmaceuticals, Inc., H2 2016 47
Pipeline by NeuClone Pty Ltd, H2 2016 48
Pipeline by Novavax, Inc., H2 2016 49
Pipeline by Regeneron Pharmaceuticals Inc, H2 2016 50
Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 51
Pipeline by TechnoVax, Inc., H2 2016 52
Pipeline by The International Biotechnology Center (IBC) Generium, H2 2016 53
Pipeline by Vaxart Inc, H2 2016 54
Pipeline by VBI Vaccines Inc, H2 2016 55
Pipeline by VLP Biotech, Inc., H2 2016 56
Dormant Projects, H2 2016 121
Discontinued Products, H2 2016 122
List of Figures
Number of Products under Development for, H2 2016 12
Number of Products under Development by Therapy Area, H2 2016 13
Number of Products under Development by Indication, H2 2016 14
Comparative Analysis by Late Stage Development, H2 2016 15
Comparative Analysis by Early Stage Products, H2 2016 16
Assessment by Monotherapy/Combination Products, H2 2016 23
Number of Products by Stage and Mechanism of Actions, H2 2016 24
Number of Products by Routes of Administration, H2 2016 25
Number of Products by Stage and Routes of Administration, H2 2016 25
Number of Products by Molecule Types, H2 2016 27
Number of Products by Stage and Molecule Type, H2 2016 27
